# OFFICE OF GENERIC DRUGS

## Review of Dissolution Data in Supplemental ANDAs

**CONTENTS**



## PURPOSE

- This MAPP specifies the responsibilities of the Office of Generic Drugs' Division of Chemistry I, Division of Chemistry II, and Division of Bioequivalence for the review of dissolution data in supplemental abbreviated new drug applications (ANDAs).

## BACKGROUND

- A memorandum of understanding was drafted in 1991 by the Division of Chemistry I, the Division of Chemistry II, and the Division of Bioequivalence (DBE) to specify dissolution testing review responsibilities for immediate-release products in supplemental applications. This memo was revised in March 1992 by the Directors of the Office of Drug Evaluation I, the Office of Drug Evaluation II, and the Office of Generic Drugs, to include the review of dissolution testing for specific changes to extended-release products in NDAs as well as ANDAs.

- Scale-up and postapproval changes (SUPAC) guidances have been issued that defined levels of change involving scale-up, formulation, manufacturing equipment and process, and site changes. Specific dissolution testing is requested for each level of change. Depending on the level, the dissolution testing ranges from single-point and comparative multi-point dissolution profiles using the application approved methods to dissolution profiles in multiple media.

- This document describes the chemistry and bioequivalence responsibilities for review of dissolution testing submitted in supplemental ANDAs that use the testing recommendations specified in the SUPAC guidances.

## REFERENCES

- SUPAC-IR: FDA guidance for industry on *Immediate-Release Solid Oral Dosage Forms: Scale-Up and Post-Approval Changes: Chemistry, Manufacturing, and Controls, In Vitro Dissolution Testing and In Vivo Bioequivalence Documentation*

- SUPAC-MR: FDA guidance for industry on *Modified-Release Solid Oral Dosage Forms: Scale-Up and Post-Approval Changes: Chemistry, Manufacturing, and Controls, In Vitro Dissolution Testing and In Vivo Bioequivalence Documentation*

---

## POLICY

- If in vitro dissolution testing calls for the use of the compendial- or ANDA-approved method, whether single-point or multi-point dissolution profiles, the reviewers of the Divisions of Chemistry I and II will evaluate the data (except for the situation detailed below).

- If new dissolution methods are requested, if there are changes to the formulation, or if there is a request for a waiver of in vivo testing for a new strength, a reviewer in the Division of Bioequivalence will evaluate the dissolution data. The DBE will also review dissolution data for low solubility drugs or drugs requiring dissolution in multiple media (i.e., extended-release products) in all instances.

---

## RESPONSIBILITIES

**Document Room Personnel will:**

- Initially assign all supplements that appear to be chemistry, manufacturing, and controls (CMC) supplements to the Divisions of Chemistry I and II.

- Assign supplements to the DBE after consultation with the chemistry project manager and/or chemistry team leader if the supplements contain in vivo studies, in vivo/in vitro correlations, multiple media dissolution data, requests for new methods, changes in formulation, or new strengths.

**The Chemistry Project Manager and Team Leader will:**

- Receive all supplements, determine whether a bioequivalence review is needed, and instruct Document Room personnel to make the review assignments accordingly.

**The Chemistry Reviewer will:**

- Review submitted dissolution data using U.S. Pharmacopeia- or ANDA-approved methods for changes specified in the guidances.

**The Bioequivalence Project Manager will:**

- Ensure that bioequivalence supplements are assigned to the next available reviewer.

**The Bioequivalence Reviewer will:**

- Review supplements containing changes in formulation, new strengths, dissolution testing containing multiple media (e.g., extended-release products or poorly soluble drugs), new methods, and/or new specifications.

---

## PROCEDURES

- The Document Room receives the supplements and verifies the appropriate review disciplines for assignments with the chemistry project manager and/or team leader. The reviewer in the Division of Chemistry will review the CMC data. If a DBE review is necessary, the supplement is forwarded to the DBE project manager for assignment to the next available bioequivalence reviewer, who will review the dissolution data.

- When the bioequivalence review is completed, the bioequivalence project manager forwards it to the chemistry project manager, who will inform the chemistry reviewer. The chemistry reviewer will complete the supplement review and the Division of Chemistry will inform the sponsor of the results.

---

## EFFECTIVE DATE

- This MAPP is effective upon date of publication.